Overview

Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain

Status:
Withdrawn
Trial end date:
2019-02-28
Target enrollment:
0
Participant gender:
All
Summary
The investigators will test whether hypotonic (diluted) remodulin solution causes less pain than the eutonic (undiluted) solution supplied by the manufacturer.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Jewish General Hospital
Treatments:
Pharmaceutical Solutions
Treprostinil
Criteria
Inclusion Criteria:

- PAH by standard criteria

- Treatment with subcutaneous remodulin infusion for at least 3 months, with stable dose
for 1 month

- Pain at infusion site (defined as > 8 on McGill Pain Questionnaire)

Exclusion Criteria:

- Known pregnancy or breastfeeding